| Membrane transporters in drug development Nature reviews Drug discovery 9 (3), 215-236, 2010 | 3608 | 2010 |
| Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo S Hoffmeyer, O Burk, O Von Richter, HP Arnold, J Brockmöller, A Johne, ... Proceedings of the National Academy of Sciences 97 (7), 3473-3478, 2000 | 3390 | 2000 |
| Metabolic gene polymorphism frequencies in control populations S Garte, L Gaspari, AK Alexandrie, C Ambrosone, H Autrup, JL Autrup, ... Cancer Epidemiology Biomarkers & Prevention 10 (12), 1239-1248, 2001 | 1146 | 2001 |
| Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects I Cascorbi, T Gerloff, A Johne, C Meisel, S Hoffmeyer, M Schwab, ... Clinical Pharmacology & Therapeutics 69 (3), 169-174, 2001 | 934 | 2001 |
| Combined Analysis of Inherited Polymorphisms in Arylamine N-Acetyltransferase 2, Glutathione S-Transferases M1 and T1, Microsomal Epoxide Hydrolase, and … J Brockmöller, I Cascorbi, R Kerb, I Roots Cancer Research 56 (17), 3915-3925, 1996 | 478 | 1996 |
| A C4887A Polymorphism in Exon 7 of Human CYP1A1: Population Frequency, Mutation Linkages, and Impact on Lung Cancer Susceptibility I Cascorbi, J Brockmöller, I Roots Cancer research 56 (21), 4965-4969, 1996 | 457 | 1996 |
| Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs I Cascorbi Pharmacology & therapeutics 112 (2), 457-473, 2006 | 452 | 2006 |
| Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population EA Gaikovitch, I Cascorbi, PM Mrozikiewicz, J Brockmöller, R Frötschl, ... European journal of clinical pharmacology 59, 303-312, 2003 | 450 | 2003 |
| Deposition of Alzheimer's β-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans S Vogelgesang, I Cascorbi, E Schroeder, J Pahnke, HK Kroemer, ... Pharmacogenetics and Genomics 12 (7), 535-541, 2002 | 449 | 2002 |
| Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis M Schwab, E Schaeffeler, C Marx, MF Fromm, B Kaskas, J Metzler, ... Gastroenterology 124 (1), 26-33, 2003 | 436 | 2003 |
| Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. I Cascorbi, N Drakoulis, J Brockmöller, A Maurer, K Sperling, I Roots American journal of human genetics 57 (3), 581, 1995 | 431 | 1995 |
| Modulation of steady‐state kinetics of digoxin by haplotypes of the P‐glycoprotein MDR1 gene A Johne, K Köpke, T Gerloff, I Mai, S Rietbrock, C Meisel, S Hoffmeyer, ... Clinical Pharmacology & Therapeutics 72 (5), 584-594, 2002 | 419 | 2002 |
| Mental and physical distress is modulated by a polymorphism in the 5-HT transporter gene interacting with social stressors and chronic disease burden HJ Grabe, M Lange, B Wolff, H Völzke, M Lucht, HJ Freyberger, U John, ... Molecular psychiatry 10 (2), 220-224, 2005 | 370 | 2005 |
| Drug interactions—principles, examples and clinical consequences I Cascorbi Deutsches Ärzteblatt International 109 (33-34), 546, 2012 | 352 | 2012 |
| CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis RJ Hung, P Boffetta, J Brockmöller, D Butkiewicz, I Cascorbi, ML Clapper, ... Carcinogenesis 24 (5), 875-882, 2003 | 329 | 2003 |
| Functional gene variants of CYP3A4 AN Werk, I Cascorbi Clinical Pharmacology & Therapeutics 96 (3), 340-348, 2014 | 308 | 2014 |
| MDR1‐P‐Glycoprotein (ABCB1) Mediates Transport of Alzheimer’s Amyloid‐β Peptides—Implications for the Mechanisms of Aβ Clearance at the Blood–Brain Barrier D Kuhnke, G Jedlitschky, M Grube, M Krohn, M Jucker, I Mosyagin, ... Brain Pathology 17 (4), 347-353, 2007 | 298 | 2007 |
| Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication I Cascorbi European Journal of Clinical Investigation 33, 17-22, 2003 | 284 | 2003 |
| The effects of the human MDR1 genotype on the expression of duodenal P‐glycoprotein and disposition of the probe drug talinolol W Siegmund, K Ludwig, T Giessmann, P Dazert, E Schroeder, B Sperker, ... Clinical pharmacology & therapeutics 72 (5), 572-583, 2002 | 269 | 2002 |
| Should We Use N-Acetyltransferase Type 2 Genotyping To Personalize Isoniazid Doses? M Kinzig-Schippers, D Tomalik-Scharte, A Jetter, B Scheidel, V Jakob, ... Antimicrobial agents and chemotherapy 49 (5), 1733-1738, 2005 | 259 | 2005 |
